

**HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP  
(HMPWG)**

**PREAMBLE TO THE CONSOLIDATED LIST OF JUSTIFIED HOMEOPATHIC STOCKS**

BASED ON THE DOCUMENT “PREAMBLE TO THE 1 <sup>ST</sup> LIST OF JUSTIFIED HOMEOPATHIC STOCKS” ADOPTED BY THE HMPWG by written procedure	14 October 2013
APPLICATION TO THE LISTS TO HOMEOPATHIC VETERINARY MEDICINAL PRODUCTS: STATEMENT ADOPTED BY THE HMPWG	5 June 2014
UPDATE (PREAMBLE TO THE CONSOLIDATED LIST OF JUSTIFIED HOMEOPATHIC STOCKS): DISCUSSION WITHIN THE SUBGROUP	1 October 2015
UPDATE: ADOPTED BY THE SUB-WORKING GROUP ON HOMEOPATHIC USE by written procedure	30 October 2015
DISCUSSION IN THE HMPWG	12 November 2015
UPDATE: ADOPTED BY THE HMPWG by written procedure	9 December 2015
TRANSMISSION TO HMA for release for consultation	10 December 2015
DEADLINE FOR COMMENTS	11 March 2016
ADOPTION BY THE HMPWG BY WRITTEN PROCEDURE	3 June 2016
TRANSMISSION TO HMA FOR PUBLICATION	13 June 2016

## **1. Introduction**

This is a non-exhaustive list of homeopathic stocks whose homeopathic use is considered satisfactorily justified in accordance with the requirements laid down in “Points to consider on the Justification of homeopathic use of the stock (June 2012)”.

The list is comprised of:

- the name(s) of the stocks, selected as follows: first name as in the German Homeopathic Pharmacopoeia (GHP) monograph, a second name (GHP monograph) if applicable / first traditional Latin name as in the French Pharmacopoeia (FP) monograph, a second name (FP monograph) if applicable.
- a reference to the European Pharmacopoeia (Ph. Eur.) and/or in absence thereof a Pharmacopoeia currently used officially in the member states. When the GHP monograph and FP monograph refer to a Ph. Eur. monograph: GHP/FP was added in brackets after Ph. Eur. The numbers of monographs of the Ph. Eur. are mentioned.
- the description of the raw material as defined in the Pharmacopoeia.
  - Chemical substance:
    - Name in English + chemical formula
  - Herbal:
    - Description in the GHP/description in the FP

## **2. Followed methodology**

The list is compiled by a subgroup of the Homeopathic Medicinal Products Working Group (HMPWG) and endorsed by all members of the HMPWG. The stocks are justified on the basis of relevant bibliographic references of literature on human use, generally available in the English language (more specifically published references accessible by the general public, related to Materia Medica and the traditional provings). For each stock, the correspondence between the homeopathic literature and the description of the stock in the official pharmacopoeias are verified.

The list is non-exhaustive, consequently, any national decisions already taken on the homeopathic use of stocks absent from the list continue to remain valid. Furthermore, if the HMPWG decides to further evaluate a well-known stock, this decision should not impact ongoing assessments or existing national decisions already taken.

## **3. Preliminary remarks**

- the mention of a Pharmacopoeial reference in the list is to ensure an official definition for each stock; it is not sufficient in itself to justify homeopathic use;
- where a monograph exists in the Ph. Eur. for a ‘homeopathic stock’, reference to this monograph is considered mandatory unless otherwise justified. This applies to all homeopathic stocks appearing in it (as refers in the directive 2001/83/ EC) and only if the definition of the stock is appropriate;

- the edition of the Pharmacopeia has not been specified (see general practice) in order to systematically refer to the current version in force,

#### **4. Strategy**

Even though pharmacopoeial references are used for definition of the homeopathic stocks reported in the list, differences related to the quality, composition, origin or parts of raw materials used are not primary concerns for the list.

For this reason, a general strategy was followed when required:

- In the case where it is not possible to know if concerned literature is related to the fresh or the dried part of a plant and both states are already being used in clinical practice without evidence to conclude a significant difference, it was decided that both states can be considered as similar forms,
- in the case where parts of the plant differ there are two entries for the same stock,
- where there are two forms of a stock (e.g. naturally occurring form and synthetic chemical) with no evidence of significant differences, the homeopathic use of both forms is considered justified on the basis of relevant bibliographic references of literature and taking into account that both are used in clinical practice.

#### **5. Application of the consolidated list to Homeopathic Veterinary medicinal products**

Bibliographic references on veterinary homeopathic use are not included in the preparation of the lists; the decision on the use of the consolidated list for the justification of the veterinary homeopathic nature of a stock shall be taken by the concerned member states on a case by case basis.